CytoDyn Announces Resolution of Class Action Lawsuit
CytoDyn announced an agreement in principle to resolve a securities class action lawsuit filed in 2021, pending final court approval.Summary
CytoDyn Inc. announced it has reached an agreement in principle to resolve a securities class action lawsuit initially filed in March 2021. The case, "Courter et al. v. CytoDyn Inc. et al.", is pending in the United States District Court for the Western District of Washington and the agreement was reached on November 23, 2025, subject to final court approval. Tyler Blok, CytoDyn’s Chief Legal Officer, stated the settlement provides clarity and benefits all stakeholders. CEO Jacob Lalezari emphasized the importance of closure for stockholders and highlighted the company’s progress with leronlimab’s clinical development, including Phase II studies in metastatic colorectal and triple-negative breast cancer, and the Expanded Access Program. CytoDyn is focused on advancing leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, for various indications including cancer.
(Source：CytoDyn Inc.)